<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, affecting the clinical response to EGFR inhibitors </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations in the EGFR kinase domain predict sensitivity to the <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> <z:chebi fb="0" ids="49668">gefitinib</z:chebi> and <z:chebi fb="0" ids="114785">erlotinib</z:chebi> in <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp>, while activating point mutations in KRAS and BRAF confer resistance to the anti-EGFR monoclonal antibody cetuximab in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The development of new generation methods for systematic mutation screening of these genes will allow more appropriate therapeutic choices </plain></SENT>
<SENT sid="3" pm="."><plain>PURPOSE: Detection of KRAS mutation in Egyptian <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients by the KRAS StripAssay </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Examination of 20 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients is done to detect KRAS mutations by KRAS StripAssay </plain></SENT>
<SENT sid="5" pm="."><plain>For the StripAssay, a mutant-enriched PCR was followed by hybridization to KRAS-specific probes bound to a <z:chebi fb="0" ids="53325">nitrocellulose</z:chebi> strip </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Among 20 patients, KRAS mutations were identified in 80% of patients by the KRAS StripAssay </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Our preliminary results suggest that KRAS StripAssay is an alternative to protocols currently in use for KRAS mutation detection </plain></SENT>
</text></document>